Lakewood-Amedex Biotherapeutics - Nu-3在临床前研究中展现良好耐受性,高剂量下系统暴露量低

美股速递
Jul 15

Lakewood-Amedex Biotherapeutics(直接上市)宣布,其候选药物Nu-3在近期完成的临床前研究中取得了积极结果。数据显示,即使在较高剂量下,Nu-3也表现出良好的耐受性,且系统暴露水平维持在较低范围。这一发现为该药物的进一步开发提供了重要的安全性依据。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10